We evaluated three commercial colistin susceptibility testing methods using 213 bloodstream Acinetobacter isolates identified by gene sequencing. Compared to the agar dilution reference method, excellent categorical agreements (both 99.1%) were observed using Vitek 2 and Etest, compared to 87.3% (95.7% for Acinetobacter baumannii and 80.7% for non-baumannii Acinetobacter isolates) using MicroScan.
A
cinetobacter species have emerged as important causative pathogens of a variety of nosocomial infections such as bacteremia, hospital-acquired pneumonia, and urinary tract infections (1) . This organism commonly presents resistance to multiple antimicrobial agents, including carbapenems (multidrug resistance), except to an "old" drug, colistin (polymyxin E), which often remains the only effective therapeutic option (2) . However, Acinetobacter strains developing resistance to colistin have recently been described (3) . Therefore, rapid and reliable methods for colistin susceptibility testing of Acinetobacter species are needed (4) .
High error rates and low levels of reproducibility of the disk diffusion method for detecting colistin resistance are well documented (4) , but Etest has shown excellent agreement with agar dilution (AD) and broth microdilution for testing colistin resistance in major Gram-negative bacteria (4) (5) (6) . However, the performance of automated antimicrobial susceptibility testing systems has rarely been assessed in terms of determining colistin susceptibility in Acinetobacter species, especially for non-baumannii Acinetobacter strains (4, 7) . In this study, by testing a broad range of Acinetobacter species isolated from blood cultures at a university hospital during a 4-year period, we evaluated the suitability of three commercial methods for colistin susceptibility testing-Vitek 2 (Vitek 2 XL; bioMérieux, Hazelwood, MO), MicroScan (MicroScan WalkAway 96 Plus; Siemens Healthcare Diagnostics Inc., Deerfield, IL), and Etest (Etest; bioMérieux SA, Marcy l'Etoile, France)-in comparison with the AD reference method.
A total of 213 nonduplicate bloodstream infection (BSI) isolates of Acinetobacter species were obtained from patient blood cultures at Chonnam National University Hospital (a 1,000-bed tertiary care hospital in Gwangju, Republic of Korea) from January 2008 to December 2011. Isolates were identified by partial rpoB gene sequencing (8) . DNA extraction and sequencing were performed as described previously (9) . Colistin susceptibility testing with the Etest (Colistin CO 256), Vitek 2 (Gram-negative susceptibility card AST-N132), and MicroScan (Gram-negative breakpoint combo panel type 42) methods was performed according to the manufacturers' instructions. The AD method was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines (10, 11) . Categorical results of each method were analyzed on the basis of the CLSI breakpoint for colistin (MIC of Յ2 g/ml, susceptible [S], and MIC of Ն4 g/ml, resistant) (11) . Categorical agreement (CA) was defined as the percentage of isolates classified into the same category by the AD reference method, and very major error (VME) and major error (ME) were defined as described previously (12) .
Of all 213 Acinetobacter BSI isolates, 13 (6.1%) demonstrated colistin resistance (MIC of Ն4 g/ml) by the AD method, which included 10 isolates of Acinetobacter genomic species 13BJ (GS13BJ), two isolates of A. junii, and one isolate of A. nosocomialis. Overall, 100% (94/94) isolates of A. baumannii were susceptible to colistin, while 10.9% (13/119) isolates of non-baumannii Acinetobacter species were resistant. This finding supports previous reports showing that resistance to colistin may be more common in non-baumannii Acinetobacter isolates than in A. baumannii (13) . For all 213 isolates, excellent CA (both Ն99%) with AD was observed with Vitek 2 and Etest, but CA with AD using MicroScan was 87.3% (Table 1) .
To date, only two studies have investigated the performance of Vitek 2 for colistin susceptibility testing using clinical isolates of Acinetobacter species (4, 7). However, as only 2 of the 67 isolates in these studies were colistin resistant, it is not possible to draw definitive conclusions regarding the efficacy of the Vitek 2 system for detection of colistin resistance in Acinetobacter species until more resistant isolates are tested (4, 7) . In this study, we tested 213 BSI a The colistin MIC ranges tested were Յ0.5 to Ͼ32 g/ml by the agar dilution method. The colistin MIC ranges determined by Vitek 2 were Յ0.5 to Ն16 g/ml, and MICs of Ն16 g/ml determined by Vitek 2 were presented as 16 g/ml. The colistin MIC ranges determined by MicroScan were Յ2 to Ͼ4 g/ml, and MICs of Յ2 and Ͼ4 g/ml determined by MicroScan were presented as 2 and 8 g/ml, respectively. Etest MICs were rounded up to the next 2-fold dilution value.
isolates, including 13 isolates of colistin-resistant Acinetobacter species. Vitek 2 showed excellent CA with 0.9% VMEs and no ME. Etest also showed excellent CA with AD for both A. baumannii (98.9%) and non-baumannii Acinetobacter species (99.2%). Although colistin Etest gives high error rates for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia (14) , our data showed no VME and only 0.9% MEs of the colistin Etest for Acinetobacter species, results which are in agreement with other reports (4, 7) .
The performance of MicroScan for colistin susceptibility testing has not been reported. In our study, the CA with AD for MicroScan was 95.7% for A. baumannii but 80.7% for non-baumannii Acinetobacter isolates. MicroScan produced VMEs in two isolates of Acinetobacter GS13BJ and MEs in 25 isolates, composed of 4.3% (4/94) A. baumannii and 17.6% (21/119) non-baumannii Acinetobacter species, suggesting that non-baumannii Acinetobacter species rather than A. baumannii were the main source of errors. Reasons for the low CA with MicroScan are unknown. However, MicroScan generated the narrowest distribution of colistin MICs (Յ2 to Ͼ4 g/ml), compared with Etest (0.016 to 256 g/ ml) or Vitek 2 (Յ0.5 to Ն16 g/ml). Considering the CLSI breakpoint for colistin (susceptible [S], Յ2 g/ml; resistant Ն 4 g/ml), the presence of only three point (Յ2, 4, and Ͼ4 g/ml) determinations of colistin MICs in the MicroScan system appears to create difficulty in differentiating colistin-resistant from -susceptible Acinetobacter isolates.
The limitation of our study is that no colistin-resistant A. baumannii isolates were tested. However, our study included 10 isolates of Acinetobacter GS13BJ, which has consistently been reported to be resistant to colistin (1, 13, 15) . In the present study, of 10 Acinetobacter GS13BJ isolates, 10 (100%), 9 (90%), 8 (80%), and 10 (100%) had a colistin MIC of Ն4 g/ml by AD, Vitek 2, MicroScan, and Etest, respectively. These data suggest that Acinetobacter GS13BJ is innately resistant to colistin and that the AD and Etest, followed by Vitek 2, have the best ability to detect colistin resistance in this species.
In conclusion, our findings indicate, for the first time, that the MicroScan is unsuitable for colistin susceptibility testing of Acinetobacter species, especially non-baumannii Acinetobacter species, due to its low reliability; in contrast, Etest and Vitek 2 are useful methods for discrimination of colistin-resistant and -susceptible Acinetobacter isolates.
